http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2518313-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5d62439409b1cd88b2de6fd5934f6e7f |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 |
| filingDate | 2012-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4423dde755aff5234dd3d8f0986c545 |
| publicationDate | 2014-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2518313-C2 |
| titleOfInvention | Perfluorinated blood substitute - gas transport donor blood substitute: formulation and treatment |
| abstract | FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to pharmaceutical industry and represents a formulation of a perfluorinated blood substitute emulsion for biomedical applications, containing: perfluorinated hydrocarbons, emulsifying agents and an electrolyte solution differing by the fact that it contains a binary mixture of two perfluorinated hydrocarbons in ratio 1.55 to 1.99 in the concentration of 5 - 1000 g/l, with an average particle size of a perfluororganic compound of 25 - 250 nm; a binary mixture of the emulsifying agents in ratio 1.55 to 1.99 that are non-ionic block copolymers of ethylene oxide and propylene oxide - proxanoles: proxanole-268/proxanole-168; proxanole-268 in the concentration of 1 - 200 g/l with the molecular weight of 7 - 14 thousand Da; proxanole-168 in the concentration of 1 - 200 g/l with the molecular weight of 5 - 7 thousand Da; the electrolyte solution: NaH 2 PO 4 - 0.18-0.25 g/l; NaCl - 5.5-6.5 g/l; and/or KCl - 0.37-0.41 g/l; and/or MgCl 2 - 0.17-0.21 g/l; and/or NaHCO 3 - 0.35-0.7 g/l; and/or glucose - 1.5-2.5 g/l. n EFFECT: invention ensures formulating the perfluorinated blood substitute with better aggregation and sedimentation stability and lower toxicity. n 2 cl, 9 ex |
| priorityDate | 2012-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 44.